No connection

Search Results

INCY

BULLISH
$95.72 Live
Incyte Corporation · NASDAQ
Target $107.36 (+12.2%)
$57.77 52W Range $112.29
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 28, 2026
Market cap
$19.05B
P/E
14.93
ROE
29.9%
Profit margin
25.0%
Debt/Equity
0.01
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
Incyte Corporation exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a negligible Debt/Equity ratio of 0.01. The company is growing rapidly, with YoY revenue growth of 27.8% and earnings growth of 43.6%, while trading at a highly attractive PEG ratio of 0.34. Despite a bearish technical trend and insider selling, the current price of $95.72 sits significantly below the growth-based intrinsic value of $189.09. The combination of high ROE (29.87%) and strong liquidity makes this a compelling value-growth opportunity.

Key Strengths

Strong financial health indicated by a Piotroski F-Score of 8/9
Exceptional growth profile with 43.6% YoY earnings growth
Virtually debt-free balance sheet (Debt/Equity 0.01)
Highly undervalued relative to growth (PEG Ratio 0.34)
Strong profitability metrics including 29.87% ROE and 25.03% profit margin

Key Risks

Bearish insider sentiment with $8.55M in net selling over 6 months
Negative technical trend (0/100) suggesting short-term price pressure
High historical earnings volatility with significant quarterly misses (e.g., 2024-07-30)
Lack of dividend yield for income-focused investors
Dependence on biotech pipeline success typical of the sector
AI Fair Value Estimate
Based on comprehensive analysis
$145.18
+51.7% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
68
Strong
Value
88
Future
90
Past
65
Health
98
Dividend
0
AI Verdict
Strong Value/Growth Play
Key drivers: Piotroski F-Score, PEG Ratio, Debt/Equity Ratio, Revenue Growth
Confidence
85%
Value
88/100

Ref P/E, PEG, Graham Number

Positives
  • Forward P/E of 10.99 is low for biotech
  • PEG of 0.34 suggests significant undervaluation
Watchpoints
  • Trading above the defensive Graham Number ($61.28)
Future
90/100

Ref Growth rates

Positives
  • Strong YoY Revenue (27.8%) and Earnings (43.6%) growth
Watchpoints
  • Recent Q/Q EPS growth decline (-35.4%)
Past
65/100

Ref Historical trends

Positives
  • Strong 1-year price performance (+60.8%)
Watchpoints
  • Erratic earnings track record with extreme surprises
Health
98/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • Piotroski F-Score 8/9
  • Current Ratio 3.32
  • Debt/Equity 0.01
Watchpoints
No urgent risks highlighted.
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend payments

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$95.72
Analyst Target
$107.36
Upside/Downside
+12.2%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for INCY and closest competitors.

Updated 2026-04-27
INC
Incyte Corporation
Primary
5Y
+12.8%
3Y
+28.6%
1Y
+60.8%
6M
+2.8%
1M
+6.0%
1W
-1.2%
ILM
Illumina, Inc.
Peer
5Y
-67.1%
3Y
-45.5%
1Y
+55.4%
6M
+29.8%
1M
-7.2%
1W
-2.2%
EXA
Exact Sciences Corp
Peer
5Y
-16.4%
3Y
+58.3%
1Y
+122.8%
6M
+95.9%
1M
+1.4%
1W
+1.0%
ZBH
Zimmer Biomet Holdings, Inc.
Peer
5Y
-38.9%
3Y
-27.0%
1Y
-18.2%
6M
-7.5%
1M
-8.3%
1W
+4.1%
MRN
Moderna, Inc.
Peer
5Y
-61.7%
3Y
-66.9%
1Y
+79.2%
6M
+96.7%
1M
-3.9%
1W
-1.1%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
14.93
Forward P/E
10.99
PEG Ratio
0.34
P/B Ratio
3.68
P/S Ratio
3.71
EV/Revenue
3.02
EV/EBITDA
10.78
Market Cap
$19.05B

Profitability

Profit margins and return metrics

Profit Margin 25.03%
Operating Margin 25.57%
Gross Margin 52.89%
ROE 29.87%
ROA 13.57%

Growth

Revenue and earnings growth rates

Revenue Growth +27.8%
Earnings Growth +43.6%
Q/Q Revenue Growth +27.84%
Q/Q Earnings Growth +48.7%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.01
Low debt
Current Ratio
3.32
Strong
Quick Ratio
3.04
Excellent
Cash/Share
$17.99

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$1.5B
Gross Margin
92.0%
Op. Margin
25.5%
Net Margin
19.9%
Total Assets
$7.0B
Liabilities
$1.8B
Equity
$5.2B
Debt/Equity
0.35x
Operating CF
$0.5B
CapEx
$-0.0B
Free Cash Flow
$0.5B
FCF Yield
96%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-28
$N/A
2026-02-10
$1.46
-3.1% surprise
2025-10-28
$2.26
+38.0% surprise
2025-07-29
$1.57
+6.6% surprise

Healthcare Sector Comparison

Comparing INCY against 560 companies in the Healthcare sector (34 bullish, 167 neutral, 359 bearish)
P/E Ratio
14.93
This Stock
vs
75.44
Sector Avg
-80.2% (Discount)
Return on Equity (ROE)
29.87%
This Stock
vs
-88.14%
Sector Avg
-133.9% (Below Avg)
Profit Margin
25.03%
This Stock
vs
-16.28%
Sector Avg
-253.7% (Weaker)
Debt to Equity
0.01
This Stock
vs
2.66
Sector Avg
-99.6% (Less Debt)
Revenue Growth
27.8%
This Stock
vs
124.04%
Sector Avg
-77.6% (Slower)
Current Ratio
3.32
This Stock
vs
4.47
Sector Avg
-25.9% (Weaker)

Similar Companies

Peer comparison within the same industry

INCY Incyte Corporation
BULLISH
Mkt Cap
$19.0B
P/E
14.9
ROE
29.9%
Price
$95.72
ILMN Illumina, Inc.
NEUTRAL
Mkt Cap
$18.8B
P/E
22.6
ROE
33.4%
Price
$123.26
 Compare with INCY
EXAS Exact Sciences Corp
BEARISH
Mkt Cap
$20.0B
P/E
-
ROE
-8.7%
Price
$104.91
 Compare with INCY
ZBH Zimmer Biomet...
NEUTRAL
Mkt Cap
$18.0B
P/E
25.6
ROE
5.6%
Price
$90.97
 Compare with INCY
MRNA Moderna, Inc.
BEARISH
Mkt Cap
$20.1B
P/E
-
ROE
-28.9%
Price
$50.8
 Compare with INCY

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

CAGNONI PABLO J
President
Sell
2026-04-17
18,667 shares · $1,801,366
CAGNONI PABLO J
President
Option Exercise
2026-04-17
18,667 shares · $1,296,046
MEURY WILLIAM
Chief Executive Officer
Stock Award
2026-04-15
125,000 shares
STEIN STEVEN H.
Officer
Stock Award
2026-04-15
39,049 shares
CAGNONI PABLO J
Officer
Stock Award
2026-04-15
27,892 shares
BAKER BROS ADVISORS L.P.
Beneficial Owner of more than 10% of a Class of Security
Stock Award
2026-03-31
842 shares
HARRIGAN EDMUND P. M.D.
Director
Stock Award
2026-03-31
269 shares · $25,318
CLANCY PAUL J.
Director
Stock Award
2026-03-31
265 shares · $24,942
CAGNONI PABLO J
Officer
Sell
2026-03-17
18,667 shares · $1,759,178
CAGNONI PABLO J
Officer
Option Exercise
2026-03-17
18,667 shares · $1,177,355
CAGNONI PABLO J
Officer
Sell
2026-02-19
18,668 shares · $1,883,788
CAGNONI PABLO J
Officer
Option Exercise
2026-02-19
18,668 shares · $1,149,702
MORRISSEY MICHAEL JAMES
Officer
Stock Award
2026-01-16
7,426 shares
HEESON LEE
Officer
Stock Award
2026-01-16
8,911 shares
ISSA MOHAMED KHAIRIE
Officer
Sell
2026-01-07
10,856 shares · $1,184,064
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-03-30
8-K
8-K
2026-03-26
8-K
8-K
2026-03-06

Incyte Corporation reported its fourth-quarter and full-year financial results for the fiscal year ended December 31, 2025.

10-K
10-K
2026-02-10

Incyte Corporation (INCY) filed its 10-K annual report on February 10, 2026. Because the provided excerpts contain only section headers without detailed text, specific financial highlights and risk factors are not available for summary.

8-K
8-K
2026-02-10
8-K
8-K
2025-12-12
10-Q
10-Q
2025-10-28

For the nine months ended September 30, 2025, INCY reported no significant changes to its critical accounting policies and is currently evaluating the impact of several new FASB accounting standards. The company faces material risks from competition for its product JAKAFI, specifically from major pharmaceutical firms and the potential entry of generic versions via the Hatch-Waxman Act.

8-K
8-K
2025-10-28

Incyte Corporation likely filed this 8-K to announce its third-quarter financial results.

8-K
FORM 8-K
2025-10-03

Incyte Corporation reported its third-quarter financial results.

8-K
8-K
2025-08-07

Incyte Corporation reported its second-quarter financial results.

10-Q
10-Q
2025-07-29
8-K
8-K
2025-07-29
8-K
FORM 8-K
2025-06-27
8-K
8-K
2025-06-11
8-K
8-K
2025-05-14
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
22 analysts
HC Wainwright & Co.
2026-04-15
reit
Buy Buy
HC Wainwright & Co.
2026-03-30
reit
Buy Buy
UBS
2026-03-25
Maintains
Neutral Neutral
HC Wainwright & Co.
2026-03-25
reit
Buy Buy
Jefferies
2026-03-16
down
Buy Hold
HC Wainwright & Co.
2026-03-09
reit
Buy Buy
Evercore ISI Group
2026-03-05
Maintains
In-Line In-Line
Barclays
2026-02-18
Maintains
Overweight Overweight
RBC Capital
2026-02-11
Maintains
Sector Perform Sector Perform
Stifel
2026-02-11
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning INCY from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile